FLDM - Fluidigm Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.6500
+0.0100 (+0.27%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.6400
Open3.6400
Bid3.0500 x 2900
Ask4.2900 x 4000
Day's Range3.4500 - 3.6700
52 Week Range2.1200 - 14.9000
Volume291,957
Avg. Volume835,085
Market Cap253.912M
Beta (5Y Monthly)2.29
PE Ratio (TTM)N/A
EPS (TTM)-0.9700
Earnings DateApr 29, 2020 - May 03, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.20
  • Fluidigm Corporation Just Reported Earnings, And Analysts Cut Their Target Price
    Simply Wall St.

    Fluidigm Corporation Just Reported Earnings, And Analysts Cut Their Target Price

    Last week, you might have seen that Fluidigm Corporation (NASDAQ:FLDM) released its full-year result to the market...

  • GlobeNewswire

    Fluidigm to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Feb. 12, 2020 -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive.

  • Thomson Reuters StreetEvents

    Edited Transcript of FLDM earnings conference call or presentation 10-Feb-20 10:00pm GMT

    Q4 2019 Fluidigm Corp Earnings Call

  • Fluidigm (FLDM) Reports Q4 Loss, Tops Revenue Estimates
    Zacks

    Fluidigm (FLDM) Reports Q4 Loss, Tops Revenue Estimates

    Fluidigm (FLDM) delivered earnings and revenue surprises of 72.73% and 4.38%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Fluidigm Announces Fourth Quarter and Full Year 2019 Financial Results

    Fourth quarter revenue of $32.4 million Full year 2019 revenue increased 4 percent to $117.2 million; full year mass cytometry revenue increased 23 percent Landmark Nature.

  • GlobeNewswire

    Fluidigm Establishes Center of Excellence at NCI-Designated Comprehensive Cancer Center to Advance Imaging Mass Cytometry

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will establish a new Center of Excellence (CoE) for Imaging Mass Cytometry™ at Georgetown Lombardi Comprehensive Cancer Center, an NCI-designated Comprehensive Cancer Center in Washington, DC. The Fluidigm® CoE program will broaden the pace of adoption of mass cytometry through the development of new highly multiplexed panels for the study of cancer, immuno-oncology and immune-mediated diseases.

  • ACCESSWIRE

    Fluidigm Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 10, 2020 / Fluidigm Corp. (NASDAQ:FLDM) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 10, 2020 at 5:00 ...

  • GlobeNewswire

    Fluidigm CyTOF Technology Selected by Covance to Develop Highly Multiplexed Human Immune Profiling Services

    SOUTH SAN FRANCISCO, Calif., Feb. 10, 2020 -- Fluidigm (Nasdaq:FLDM) today announced that Covance, the drug development business of LabCorp® (NYSE: LH), a leading global life.

  • Earnings Preview: Fluidigm (FLDM) Q4 Earnings Expected to Decline
    Zacks

    Earnings Preview: Fluidigm (FLDM) Q4 Earnings Expected to Decline

    Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Those Who Purchased Fluidigm (NASDAQ:FLDM) Shares Five Years Ago Have A 90% Loss To Show For It
    Simply Wall St.

    Those Who Purchased Fluidigm (NASDAQ:FLDM) Shares Five Years Ago Have A 90% Loss To Show For It

    Fluidigm Corporation (NASDAQ:FLDM) shareholders should be happy to see the share price up 16% in the last month. But...

  • GlobeNewswire

    Landmark Nature Publication Demonstrates the Power of the Fluidigm Hyperion Imaging System to Identify Novel Cellular Signatures That Correlate with Distinct Clinical Outcomes

    Fluidigm Corporation (FLDM), the global leader in high-multiplex single-scan tissue imaging, today announced that a new landmark study demonstrates the potential for Imaging Mass Cytometry™ (IMC™) on the Hyperion™ Imaging System to transform tissue pathology by identifying cellular signatures within tissue microenvironments that correlate with clinical outcomes. The innovative study suggests highly multiplexed spatial information at single-cell resolution has the potential to improve patient-specific treatment selection in the future. Researchers at the University of Zurich, University of Cambridge and University of Basel conducted the 352-patient study, results of which have been published today in Nature1.

  • GlobeNewswire

    Fluidigm Provides Preliminary Financial Results for Fourth Quarter and Fiscal Year 2019

    Fluidigm Corporation (FLDM) today provided preliminary financial highlights for the fourth quarter ended December 31, 2019. Mass cytometry fourth quarter annualized consumables pull-through of approximately $72 thousand.

  • GlobeNewswire

    MOgene Selects Fluidigm Advanta Assays and Juno System to Expand Its NGS Services Portfolio

    SOUTH SAN FRANCISCO, Calif., Jan. 13, 2020 -- MOgene, a leading provider of genomic and bioinformatic services in St. Louis, today announced it has selected Fluidigm’s.

  • GlobeNewswire

    The University of Michigan Protein Assembly Lab Selects Hyperion Imaging System for Research In Cancer Immunotherapy and Immune Phenotyping

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that The University of Michigan Protein Assembly Lab, a hub for collaborative and innovative research at the intersection of synthetic biology, protein engineering and personalized medicine, has chosen the Hyperion™ Imaging System to expand its capabilities in multiparameter imaging and immune profiling of tissue. Building upon important research enabled by mass cytometry since 2016, the lab acquired a Hyperion Imaging System to expand its capabilities in multiparameter spatial analysis of the tissue microenvironment. The Protein Assembly Lab is under the direction of Fei Wen, PhD, Associate Professor and Associate Chair for Undergraduate Education in Chemical Engineering, Director of the UM Mass Cytometry Core and Co-Director of the Immune Monitoring Shared Resource at the UM Rogel Cancer Center.

  • Is Fluidigm (NASDAQ:FLDM) Using Debt In A Risky Way?
    Simply Wall St.

    Is Fluidigm (NASDAQ:FLDM) Using Debt In A Risky Way?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • GlobeNewswire

    Fluidigm Named to Greater Toronto's Top Employers for 2020

    Fluidigm Canada, a subsidiary of Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, has been named one of Greater Toronto's Top Employers for 2020, an annual list of organizations with exceptionally positive and engaging environments that inspire and motivate. Each year, editors at Mediacorp Canada recognize employers that have been judged to demonstrate exceptional human resources programs and forward-thinking workplace policies. “Being named an employer of choice in one of the largest cities in the Americas is a true accomplishment, and it clearly differentiates Fluidigm in the competition for talent,” said Chris Linthwaite, President and CEO.

  • GlobeNewswire

    Fluidigm Expands Maxpar Antibody Portfolio for High-Multiplex Tissue Imaging

    Fluidigm Corporation (FLDM), the global leader in high-multiplex single-scan tissue imaging, today announced the availability of more than 100 pathologist-verified Maxpar® antibodies for use with Imaging Mass Cytometry™ (IMC™) on the Hyperion™ Imaging System. This expanding collection now includes antibodies verified for use with both formalin-fixed, paraffin-embedded (FFPE) and frozen tissues, enabling researchers to more easily profile a larger number of sample types to power new health insights. Imaging Mass Cytometry is revolutionizing translational and clinical research by providing unprecedented visualization of complex cellular phenotypes and their relationships in the context of cancer, immuno-oncology, and immune-mediated diseases.

  • GlobeNewswire

    Fluidigm Receives Life Science Industry Award for the Maxpar Direct Immune Profiling System

    BioInformatics Inc., the leading research and advisory firm serving the life science tools market, recognized Fluidigm (FLDM) with the Gold Award for the Best New Product in Cell Biology for the Maxpar® Direct™ Immune Profiling System. The Maxpar Direct Immune Profiling System empowers researchers to easily quantify 37 different immune cell populations from human peripheral blood mononuclear cells (PBMC) and whole blood using CyTOF® technology.

  • Hedge Funds Have Never Been This Bullish On Fluidigm Corporation (FLDM)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Fluidigm Corporation (FLDM)

    Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

  • GlobeNewswire

    Fluidigm Corporation Announces Pricing of Private Offering of $50 Million of 5.25% Convertible Senior Notes

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the pricing of $50 million aggregate principal amount of 5.25% convertible senior notes due 2024 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Fluidigm also granted the initial purchasers of the notes a 13-day option to purchase up to an additional $5 million aggregate principal amount of the notes. The notes will be senior unsecured obligations of Fluidigm and will accrue interest payable semiannually in arrears on June 1 and December 1 of each year, beginning on June 1, 2020, at a rate of 5.25% per year.

  • GlobeNewswire

    Fluidigm Corporation Announces Proposed Private Offering of $45 Million of Convertible Senior Notes

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it intends to offer, subject to market conditions and other factors, $45 million of aggregate principal amount of convertible senior notes due 2024 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Fluidigm also intends to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $5 million aggregate principal amount of the notes. The notes will be senior unsecured obligations of Fluidigm and will accrue interest payable semiannually in arrears.

  • GlobeNewswire

    Fluidigm to Participate in the 31st Annual Piper Jaffray Healthcare Conference

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in the 31st Annual Piper Jaffray Healthcare Conference in New York. Chris Linthwaite, President and Chief Executive Officer, will participate in a fireside chat at the conference on Wednesday, December 4, 2019, at 1:30 pm ET. Fluidigm (FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight.

  • Analysts See 2 Falling Knives Bouncing Back
    GuruFocus.com

    Analysts See 2 Falling Knives Bouncing Back

    They have a low financial burden Continue reading...

  • Thomson Reuters StreetEvents

    Edited Transcript of FLDM earnings conference call or presentation 5-Nov-19 10:00pm GMT

    Q3 2019 Fluidigm Corp Earnings Call

  • Fluidigm (FLDM) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    Fluidigm (FLDM) Reports Q3 Loss, Misses Revenue Estimates

    Fluidigm (FLDM) delivered earnings and revenue surprises of 0.00% and -8.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?